Filtered By:
Condition: Heart Failure
Education: Study
Therapy: Statin Therapy

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 189 results found since Jan 2013.

Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial.
CONCLUSIONS: As an add-on to OMT, MUSKARDIA is safe and significantly reduces angina frequency in patients with stable CAD. Moreover, the use of MUSKARDIA is associated with a trend toward reduced MACEs in patients with stable CAD. The results suggest that MUSKARDIA can be used to manage patients with CAD. TRIAL REGISTRATION: No. ChiCTR-TRC-12003513. PMID: 33273369 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - December 2, 2020 Category: General Medicine Authors: Ge JB, Fan WH, Zhou JM, Shi HM, Ji FS, Wu Y, Zhao YL, Qian J, Jin YZ, Liu YW, Wang SH, He SH, Yang P, Wu J, Lu F, Hou ZS Tags: Chin Med J (Engl) Source Type: research

Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study
Conclusions  Larger early LDL-C reduction and more intensive statin therapy after MI were associated with a reduced hazard of all CV outcomes and all-cause mortality. This supports clinical trial data suggesting that earlier lowering of LDL-C after an MI confers the greatest benefit.
Source: European Heart Journal - December 24, 2020 Category: Cardiology Source Type: research

Effect of More Intensive LDL-C-Lowering Therapy on Long-term Cardiovascular Outcomes in Early-Phase Acute Coronary Syndrome: A Systematic Review and Meta-analysis
Clin Ther. 2021 Jun 3:S0149-2918(21)00215-0. doi: 10.1016/j.clinthera.2021.04.019. Online ahead of print.ABSTRACTPURPOSE: The effect of more intensive LDL-C-lowering therapy (ILLT) on long-term cardiovascular outcomes during the early phase of acute coronary syndromes (ACSs) remains uncertain. We aimed to explore the influence of more intensive LDL-C-lowering therapyduring the early disease phase on long-term cardiovascular events among patients with ACSs.METHODS: Randomized controlled trials that focused on the effect of more ILLT during early-phase ACSs on long-term major adverse cardiac events (MACEs) were searched in e...
Source: Clinical Therapeutics - June 7, 2021 Category: Drugs & Pharmacology Authors: Siyao Jin Xiaolu Nie Yuxi Li Jinjie Yuan Yimin Cui Libo Zhao Source Type: research

Comparing pharmacotherapy in MINOCA versus medically managed obstructive acute coronary syndrome
This study uniquely compares the management and outcomes of MINOCA patients with a medically managed obstructive ACS (M-ACS) population. We retrospectively analysed registry data for consecutive patients admitted to the Gold Coast University Hospital with ACS requiring coronary angiography and identified patients with MINOCA and M-ACS. Baseline characteristics, pharmacological therapy and in-hospital outcomes were compared. In hospital outcomes were composite NACE, heart failure, stroke and major bleeding. Multivariate regression analysis was also performed to identify independent predictors of MINOCA. Multivariate regress...
Source: Heart and Vessels - October 10, 2021 Category: Cardiology Source Type: research

Association between CRP/Albumin ratio and long-term mortality in patients with cHronIc Limb-threatening ischemia undergoing EndovaScular therapy Below The Knee: The ACHILES-BTK Registry
CONCLUSIONS: CAR was associated with mortality in CLTI patients undergoing EVT for BTK lesions. CAR may be a simple method to help patient selection, assessment, and intervention strategy for EVT and may improve patient outcomes.PMID:34896550 | DOI:10.1016/j.avsg.2021.11.008
Source: Atherosclerosis - December 13, 2021 Category: Cardiology Authors: Cafer Pan ç Arda G üler İsmail Gürbak Ömer Taşbulak Ahmet G üner Ali Kemal Kalkan Ahmet Arif Yal çın Mehmet Ert ürk Source Type: research

Comparing pharmacotherapy in MINOCA versus medically managed obstructive acute coronary syndrome
This study uniquely compares the management and outcomes of MINOCA patients with a medically managed obstructive ACS (M-ACS) population. We retrospectively analysed registry data for consecutive patients admitted to the Gold Coast University Hospital with ACS requiring coronary angiography and identified patients with MINOCA and M-ACS. Baseline characteristics, pharmacological therapy and in-hospital outcomes were compared. In hospital outcomes were composite NACE, heart failure, stroke and major bleeding. Multivariate regression analysis was also performed to identify independent predictors of MINOCA. Multivariate regress...
Source: Heart and Vessels - March 23, 2022 Category: Cardiology Source Type: research

Assessing statins use in a real-world primary care digital strategy: a cross-sectional analysis of a population-wide digital health approach
Lancet Reg Health Am. 2023 Jun 22;23:100534. doi: 10.1016/j.lana.2023.100534. eCollection 2023 Jul.ABSTRACTBACKGROUND: The digitization of the primary care system provides an opportunity to evaluate the current use of statins in secondary prevention populations (myocardial infarction or stroke).METHODS: We conducted a cross-sectional study (ClinicalTrials.gov, NCT05285085), analysing anonymised data routinely collected by community health workers (CHW) in Brazil between May 2016 and September 2021 to assess the proportion of self-reported statins use and associated factors.FINDINGS: From the 2,133,900 individuals on the da...
Source: Atherosclerosis - July 27, 2023 Category: Cardiology Authors: M Julia Machline-Carrion Alysson Nathan Girotto Josu é Nieri Pedro Marton Pereira Frederico Monfardini Francisco Forestiero Priscila Raupp Fabiana Roveda Karla Santo Ot ávio Berwanger Raul D Santos Source Type: research

Impact of Adding Aspirin to Beta-Blocker and Statin in High-Risk Patients Undergoing Major Vascular Surgery
In this study we evaluated the benefits of adding aspirin (A) to BB and S (ABBS), with/without angiotensin-converting enzyme inhibitor (ACE-I) on postoperative outcome in high-risk patients undergoing major vascular surgery.Methods: Analysis of consecutive patients undergoing elective vascular surgery at the University of Michigan Cardiovascular Center was performed. Univariate and multivariate analyses were done using cardiac risk index [Revised Cardiac Risk Index (RCRI), coronary artery disease (CAD), insulin-dependent diabetes mellitus (IDDM), cerebral vascular disease, renal dysfunction, congestive heart failure, and m...
Source: Annals of Vascular Surgery - March 25, 2013 Category: Surgery Authors: Wei C. Lau, James B. Froehlich, Elizabeth S. Jewell, Daniel G. Montgomery, Kristina M. Eng, Theresa A. Shields, Peter K. Henke, Kim A. Eagle Tags: Basic Data Underlying Clinical Decision-Making in Endovascular Therapy Source Type: research

Prognosis of Patients With Stable Coronary Artery Disease (from the CORONOR Study)
In conclusion, the mortality rate of patients with stable CAD in modern clinical practice is similar to that of the general population and is mostly due to noncardiovascular causes.
Source: The American Journal of Cardiology - January 15, 2014 Category: Cardiology Authors: Christophe Bauters, Michel Deneve, Olivier Tricot, Thibaud Meurice, Nicolas Lamblin, CORONOR Investigators Tags: Coronary Artery Disease Source Type: research

The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial
Abstract: Background: Current guidelines recommend intensive low-density lipoprotein (LDL) cholesterol lowering with statins, with a target of 70mg/dL (1.81mmol/L) LDL cholesterol for those with a very high risk of coronary artery events. However, there is no multicenter study assessing the effect of intensive lipid-lowering therapy with statins on acute coronary syndrome (ACS) in a Chinese population with low baseline LDL cholesterol levels.Methods and results: Patients (n=1355) with ACS were treated with a moderate dose of statin (atorvastatin 10 mg/d, or equivalent dose of other statins, n=675) or with an intensive dose...
Source: Atherosclerosis - March 20, 2014 Category: Cardiology Authors: Shui-ping Zhao, Bi-lian Yu, Dao-quan Peng, Yong Huo Tags: Clinical & Population Research – Intervention Source Type: research

Statins do not improve cardiovascular outcomes for dialysis patients
Commentary on: Palmer SC, Navaneethan SD, Craig JC, et al.. HMG CoA reductase inhibitors (statins) for dialysis patients: a systematic review and meta-analysis. Cochrane Database Syst Rev 2013;(9):CD004289. Context Chronic kidney disease affected nearly 19 million people in the USA, with incidence increasing globally at an annual rate of 8%, most of which were unrecognised or undiagnosed. Cardiovascular events are common among patients with chronic kidney disease and highest in dialysis patients. While dialysis patients experience a high prevalence of traditional risk factors for cardiovascular disease (CVD), such as hyper...
Source: Evidence-Based Medicine - May 19, 2014 Category: Internal Medicine Authors: Olyaei, A. Tags: Clinical trials (epidemiology), Epidemiologic studies, Drugs: cardiovascular system, Neuromuscular disease, Stroke, Hypertension, Obesity (nutrition), Ischaemic heart disease, Unwanted effects / adverse reactions, Renal medicine, Musculoskeletal syndromes Source Type: research

Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure
Conclusions Use of ACEI/ARB was not associated with better outcomes in stable CAD outpatients without HF. The benefit of ACEI/ARB seen in randomized clinical trials was not replicated in this large contemporary cohort, which questions their value in this specific subset.
Source: European Heart Journal - July 7, 2014 Category: Cardiology Authors: Sorbets, E., Labreuche, J., Simon, T., Delorme, L., Danchin, N., Amarenco, P., Goto, S., Meune, C., Eagle, K. A., Bhatt, D. L., Steg, P. G. Tags: Coronary artery disease Source Type: research

Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases.
Abstract Growing evidence indicates that overproduction of reactive oxygen species (ROS) plays a prominent role in the development of cardio- and cerebro-vascular diseases. Among the mechanisms identified to produce oxidative stress in the vascular wall, those mediated by membrane-bound NAD(P)H oxidases represents a major one. NAD(P)H oxidases are a family of enzymes that generate ROS both in phagocytic and non-phagocytic cell types. Vascular NAD(P)H oxidase contains the membrane-bound subunits Nox1, Nox2 (gp91phox), Nox4 and p22phox, the catalytic site of the oxidase, and the cytosolic components p47phox and p67p...
Source: Current Drug Targets - October 27, 2014 Category: Drugs & Pharmacology Authors: Carrizzo A, Forte M, Lembo M, Formisano L, Puca AA, Vecchione C Tags: Curr Drug Targets Source Type: research